Investors Face August Deadline in ADMA Biologics Securities Lawsuit

The complaint, Mazzarino v. ADMA Biologics, Inc., alleges that the company and its top executives violated the Securities Exchange Act of 1934 by disseminating misleading financial information. The legal action follows a March 2026 report by Culper Research, which claimed the company’s reported growth was a fiction driven by a de facto channel stuffing scheme and the extension of payment terms to artificially inflate revenues. Following the report’s publication, ADMA Biologics stock dropped more than 16%.

Additional pressure mounted on March 26, 2026, after Cantor Fitzgerald downgraded the company’s stock from Overweight to Neutral, citing concerns over the company's response to the allegations. The stock price fell an additional 13% following the downgrade. ADMA Biologics has publicly dismissed the short-seller report as being based on speculative assertions from unreliable sources. Investors seeking to participate in the class action process must meet specific financial criteria to represent the class, though individual recovery is not contingent upon serving as the lead plaintiff.